In Vitro Transcription Kits for Synthesizing High Yield mRNA |
In vitro transcription (IVT) is a common and convenient method that is critical for mRNA synthesis and RNA research.
Our Invitrogen mMessage mMachine and MEGAscript kits are the most competent kits in the industry when it comes to flexibility in producing synthetic mRNA via in vitro transcription. Invitrogen offers a unique and proven suite of products that meet critical process, scale, and quality to accelerate your mRNA discovery. This includes downstream applications, such as mRNA vaccines for infectious diseases and mRNA therapeutics for rare disease, antibody therapy, and protein therapy.
The very first in vitro transcription kits, mMessage mMachine and MEGAscript, were commercialized in 1989 under Ambion, now known as Invitrogen. While the brand has evolved, the quality and superior results remain the same. With over 50,000 citations, these kits are recognized as the most reliable and high-performing solutions in the industry, with the capability to overcome a variety of limitations with flexible offerings for synthesizing RNA.
With a variety of polymerases to choose from (T7, SP6, and T3) to transcribe a linearized DNA template or PCR-amplified DNA into mRNA, we offer a series of kits to fit your research needs. Our MEGAscript and mMessage mMachine kits allow for synthetic mRNA to be customizable with the ability to modify nucleotides, polymerases, Poly(A) Tailing Kit, and capping technologies (mCap analog, ARCA), to synthesize custom mRNA and accelerate your mRNA discovery. See our most popular in vitro transcription T7 polymerase kits below.
|
|
|
| |
| Description | Next generation in vitro transcription kit for uncapped mRNA synthesis | First generation mCap analog for capped mRNA synthesis | Offers third generation cap (natural cap found in humans) CleanCap® Reagent AG | Design offers second generation ARCA cap for mRNA synthesis |
| Benefits |
|
|
|
|
| Capping efficiency | N/A | 70–80% | ≥95% | 70–80% |
| Yield per reaction | 100 µg | 20–30 µg | ≥100 µg | 20–30 µg |
| Scalability | ++++ | ++ | ++++ | +++ |
A simple solution for RNA clean-up plus purification after in vitro transcription and other enzymatic reactions. The kit contains silica spin column solutions that efficiently separate RNA from unincorporated NTPs, enzymes, and buffer components.
Consider our custom mRNA Synthesis Services which utilize our best-in-class in vitro transcription products and team of experts to help streamline your workflow.
Figure 1. The mMessage mMachine T7 mRNA Kit with CleanCap® Reagent AG can give mRNA yields >5 mg/mL or >100 µg for a standard 20 µL reaction. The kit can give 5 times more mRNA than the mMessage mMachine T7 Ultra Transcription Kit that has the ARCA cap analog, and 1.5 times more mRNA than a leading competitor mRNA kit with CleanCap® Reagent AG. The gray bars in the plot are the average yields for 5 different templates with the different IVT kits. The different color dots indicate the average mRNA yields for each template. Green: GFP (1 kb long). Blue: Cas9 (5 kb long). Orange: Gaussia luciferase (0.8 kb long). Yellow: Firefly luciferase (2 kb long). Black: VEE self-amplifying GFP (10 kb long). Three replicates were performed for each template with each mRNA kit.
Figure 2. mRNA made by the mMessage mMachine T7 mRNA Kit with CleanCap® Reagent AG can have significantly higher cell performance than mRNA made by the mMesage mMachine T7 Ultra Transcription Kit that has the ARCA cap analog and is on par with a leading competitor mRNA kit with CleanCap Reagent AG. For this experiment, fLuc mRNA was made by each of the mRNA kits, and 25 ng of the mRNAs were transfected into A549 human lung carcinoma epithelial cells using the Lipofectamine MessengerMAX Transfection Reagent. Cell were assayed 24 hours later for luciferase activity using the Pierce Firefly Luc One-Step Glow Assay Kit.
Figure 3. The mMessage mMachine T7 mRNA Kit with CleanCap® Reagent AG can have mRNA capping efficiencies >95%. This is significantly higher than the mMessage mMachine T7 Ultra Transcription Kit that has the ARCA cap analog, and is on par with a leading competitor mRNA kit with CleanCap® Reagent AG. Average capping efficiencies were calculated from 5 different templates.
Figure 4. The mMessage mMachine T7 mRNA Kit with CleanCap® Reagent AG gives mRNA qualities similar to the mMessage mMachine T7 Ultra Transcription Kit that has the ARCA cap analog and a leading competitor mRNA kit with CleanCap® Reagent AG. The agarose gels for 5 different mRNAs show that the qualities are similar for all three kits.
Download the application note to learn more about how our mMESSAGE mMACHINE T7 mRNA Kit with CleanCap® Reagent AG works with lipid nanoparticle (LNP) technology for effective in vivo delivery of mRNA.
Download now
Learn how our MEGAscript kit was used to develop CAR T therapy targeting fibrosis
Evaluate the role of in vitro transcription in the development of novel oral vaccines utilizing self-amplifying RNA (saRNA)
For Research Use Only. Not for use in diagnostic procedures.
